What is BNTC's current stock price?

BNTC (Benitec Biopharma Inc.) is currently trading at $11.23 with a market cap of $294.8M.

What sector is Benitec Biopharma Inc. in?

Benitec Biopharma Inc. (BNTC) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is BNTC a good stock to buy?

Analysts have a Buy consensus on BNTC with a price target of $25.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

BNTC Benitec Biopharma Inc.

Healthcare

$11.23-1.14%ClosedMarket Cap: $294.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.03

P/S

0.00

EV/EBITDA

-2.07

DCF Value

$2.67

FCF Yield

-7.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-34.8%

ROA

-26.1%

ROIC

-29.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q3 null	$0.00	$-11.9M	$—
Q2 null	$0.00	$-11.8M	$—
Q1 null	$0.00	$-9.0M	$—
Q4 null	$0.00	$-16.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$25.00

Target (Median)

$25.00

Target Range

$25.00 - $25.00

1 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-03-09

HC Wainwright & Co.Buy

2025-11-24

CitizensMarket Outperform

2025-11-04

JMP SecuritiesMarket Outperform

2025-09-24

OppenheimerOutperform

2025-09-16

Trading Activity

Insider Trades

View All

Mates Sharondirector

SellMon Jan 26

SUVRETTA CAPITAL MANAGEMENT, LLCdirector, 10 percent owner:

BuyMon Dec 29

SUVRETTA CAPITAL MANAGEMENT, LLCdirector, 10 percent owner:

BuyMon Dec 29

SUVRETTA CAPITAL MANAGEMENT, LLCdirector, 10 percent owner:

BuyMon Dec 29

SUVRETTA CAPITAL MANAGEMENT, LLCdirector, 10 percent owner:

BuyMon Dec 29

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.28

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Peers

QSI